Abstract: The present disclosure relates to oral compositions that include at least two agents selected from: agents that increase the concentration of glutamate; agents that increase dopamine production; agents that increase the concentration of brain-derived neurotrophic factor (BDNF); NMDA and/or AMPA receptor modulators; and acetylcholinesterase inhibitors. In son embodiments, a composition as provided herein includes D-glutamine present in an amount of about 20% to about 30% w/w of the composition; ginkgolide B present in an amount of about 0.1% to about 0.4% w/w of the composition; phosphatidylserine present in an amount of about 65% to about 80% w/w of the composition; and ascorbic acid present in an amount of about 0.5% to about 2.5% w/w of the composition. Such compositions are useful for improving memory and/or focus.

Abstract: The present disclosure is related to dietary supplements. For example, this disclosure relates to compositions that include, one or more agents that decrease the production of tumor necrosis factor-alpha (TNF-?), decrease the CCL2, and decrease the interleukin-1 beta (IL-1?) responsible for low grade chronic inflammation. In some embodiments, the composition comprises: epicatechin present in an amount of about 0.25% to about 1% w/w of the composition; EGCG present in an amount of about 0.01% to about 0.1% w/w of the composition; lycopene present in an amount of about 1% to about 3% w/w of the composition; quercetin present in an amount of about 0.1% to about 1% w/w of the composition; luteolin present in an amount of about 0.1% to about 1% w/w of the composition; vitamin A present in an amount of about 1% to about 7.5% w/w of the composition; vitamin C present in an amount of about 40% to about 77% w/w of the composition; and vitamin E present in an amount of about 15% to about 40% w/w of the composition.

Abstract: The present disclosure is related to dietary supplements. In some aspects, this disclosure relates to compositions that can include, one or more agents that can increase the synthesis of testosterone, decrease the degradation of testosterone, and/or decrease the oxidative stress. In some embodiments, an agent of the composition includes: a mineral, a carboxylic acid, a flavone, a flavan, a terpinoid, an amino acid, a benzopyran; and a glycoside, and a combination thereof.

Abstract: The present disclosure is related to dietary supplements. For example, this disclosure relates to compositions that include, one or more agents that decrease the production of reactive oxygen species (ROS) responsible for oxidative stress, and/or decrease the concentration of ROS. In some embodiments, a composition as provided herein includes epicatechin present in an amount of about 0.1% to about 3% w/w of the composition; vitamin A acid present in an amount of about 1% to about 15% w/w of the composition; vitamin C present in an amount of about 10% to about 80% w/w of the composition; and, vitamin E present in an amount of about 5% to about 60% w/w of the composition. Such compositions are useful for improving oxidative stress by decreasing ROS concentration.

Abstract: A process and a system are disclosed for determining if a combination of a set of chemical compounds has either a synergistic, additive, or antagonistic effect on a disease, e.g., osteoarthritis, or a biological function, e.g., oxidative stress. In one step of the process, for a particular ensemble of molecular pathway models representing the disease or biological function along with the particular set of biomarkers for that disease or biological function, computation is performed to quantify for a particular set of chemical compounds, their effects individually, sequentially, and in combination on the biomarkers. In another step of the process, comparison of these effects is performed to determine if the combinations of the chemical compounds behave synergistically, additively, or antagonistically. The end results are combinations of chemical compounds along with their dosage levels, which synergistically affect disease or biological function of interest.

Abstract: The present disclosure is related to dietary supplements. For example, this disclosure relates to compositions that include, one or more agents that decrease the production of reactive oxygen species (ROS) responsible for oxidative stress, and/or decrease the concentration of ROS. In some embodiments, a composition as provided herein includes epicatechin present in an amount of about 0.1% to about 3% w/w of the composition; vitamin A acid present in an amount of about 1% to about 15% w/w of the composition; vitamin C present in an amount of about 10% to about 80% w/w of the composition; and, vitamin E present in an amount of about 5% to about 60% w/w of the composition. Such compositions are useful for improving oxidative stress by decreasing ROS concentration.

Abstract: The present disclosure is related to dietary supplements. For example, this disclosure relates to compositions that include, one or more agents that decrease the production of tumor necrosis factor-alpha (TNF-?), decrease the CCL2, and decrease the interleukin-1 beta (IL-1?) responsible for low grade chronic inflammation. In some embodiments, the composition comprises: epicatechin present in an amount of about 0.25% to about 1% w/w of the composition; EGCG present in an amount of about 0.01% to about 0.1% w/w of the composition; lycopene present in an amount of about 1% to about 3% w/w of the composition; quercetin present in an amount of about 0.1% to about 1% w/w of the composition; luteolin present in an amount of about 0.1% to about 1% w/w of the composition; vitamin A present in an amount of about 1% to about 7.5% w/w of the composition; vitamin C present in an amount of about 40% to about 77% w/w of the composition; and vitamin E present in an amount of about 15% to about 40% w/w of the composition.